Palazestrant in combination with ribociclib demonstrated encouraging activity across all dose cohorts and subgroups Median PFS was 15.5 months in the 120 mg palazestrant cohort across all patientsIn ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback